Infectious or chronic diseases such as long COVID, Alzheimer’s disease and traumatic brain injury can cause inflammation in ...

One year after being acquired by Global Alzheimer’s Platform Innovations, Tampa-based Axiom Brain Health has expanded its ...

Access to the new Alzheimer's drugs is limited by strict eligibility criteria, long wait times, and a lack of infusion ...

Xenon is one of the six noble gases. Its name derives from the Greek word for “strange”. In medicine, it has been used as an ...

The Japanese and American based pharma companies announced a win for their Alzheimer’s treatment, which has faced some negative backlash over the last year.

Lecanemab is a humanized immunoglobulin gamma 1 monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta.

The FDA approves a new maintenance dosing regimen for lecanemab (Leqembi; Eisai) in patients with early-stage Alzheimer ...

Discover the link between REM sleep and Alzheimer's disease. Learn how delayed REM sleep may indicate elevated protein levels ...

With this approval, patients who receive the anti-amyloid drug biweekly for 18 months can then consider switching to a monthly dosing regimen.

Biogen BIIB announced that the FDA has approved a monthly maintenance dosing version for its intravenously (IV) administered ...

Gaps remain in biomedical research in frontotemporal dementia; however, there are several means by which these gaps can be bridged.

In simulated trial, FDI achieved mean absolute errors of 1.57 and 0.70 years for predicting MCI, AD onset, respectively.